Roche in $1.7bn deal for breast cancer innovator Seragon
This article was originally published in Scrip
Roche's Genentech business has agreed to pay $725m up front and up to $1bn in milestone-related payments to acquire Seragon Pharmaceuticals of San Diego, California. Seragon's most advanced product is in Phase I trials, but Roche believes its technology could herald a breakthrough in cancer treatment.
You may also be interested in...
VenBio has $315m in new cash to invest in a broad array of therapeutics developers now that it has closed its second venture capital fund, which raised $65m more than the VC firm originally intended and reflects big pharma's increasing commitment to backing early-stage life science companies.
From the latest COVID-19 advances to the emergence of a game changer for heart failure, Scrip’s editor in chief Eleanor Malone reviews the big stories of the past three months. Safety issues around JAK inhibitors and AAV vector-based gene therapy were also to the fore, while biopharma financing continued apace.
A snapshot of the compensation packages of CEOs and R&D leaders of the world’s biggest pharmaceutical companies, alongside median employee pay and key company performance metrics.